Heidelberg Pharma AG

Wilex is a biopharmaceutical company focused on oncology and antibodies. The parent company WILEX AG no longer pursues clinical development activities in Munich, instead acting exclusively as a holding company. Operation concentrate on the research and development activities of the subsidiary Heidelberg Pharma GmbH in Ladenburg. Heidelberg Pharma workes with the toxin Amanitin and an ADC technology with the goal of coupling this highly effective agent with various antibodies to make it usable for treating cancer. This innovative technology platform is progressively being developed for therapeutic antibody drug conjugates for use in proprietary projects and partnerships.
  • TickerHPHA
  • ISINDE000A11QVV0
  • SectorPharmaceuticals & Biotechnology
  • CountryGermany
 PRESS RELEASE
HPHA Heidelberg Phar... (Health Care)

DGAP-News: Heidelberg Pharma gibt Update zur klinischen Phase I/IIa-St...

DGAP-News: Heidelberg Pharma AG / Schlagwort(e): Sonstiges Heidelberg Pharma gibt Update zur klinischen Phase I/IIa-Studie mit dem ATAC-Kandidaten HDP-101 in den USA 07.09.2021 / 07:21 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PRESSEMITTEILUNG Heidelberg Pharma gibt Update zur klinischen Phase I/IIa-Studie mit dem ATAC-Kandidaten HDP-101 in den USA - Kompatibilitätstests für geschlossenes Infusionssystem mit HDP-101 erfolgreich abgeschlossen- Versand der Studienmedikation in die USA in Vorbereitung- Vertrag mit erstem Studienzentrum, ...

 PRESS RELEASE
HPHA Heidelberg Phar... (Health Care)

DGAP-News: Heidelberg Pharma Provides Update on Phase I/IIa Clinical T...

DGAP-News: Heidelberg Pharma AG / Key word(s): Miscellaneous Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US 07.09.2021 / 07:21 The issuer is solely responsible for the content of this announcement.   PRESS RELEASE Heidelberg Pharma provides update on Phase I/IIa clinical trial with ATAC candidate HDP-101 in the US - Compatibility tests for closed infusion system with HDP-101 successfully completed- Shipping of study medication to the US in preparation- Contract signed with first study center, MD Anderson Cancer Ce...

Olga Smolentseva
  • Olga Smolentseva
HPHA Heidelberg Phar... (Health Care)

HEIDELBERG PHARMA: H1 2021 brings closer to value inflection point | ...

HEIDELBERG PHARMA - BUY | EUR12 (+60%) H1 2021 brings closer to value inflection point Phase I/II study of HDP-101 is now expected to start recruitment in Q3 Partners are moving along with ATACs development Reiterating BUY rating and TP EUR12

Olga Smolentseva
  • Olga Smolentseva
HPHA Heidelberg Phar... (Health Care)

HEIDELBERG PHARMA (BUY, TP EUR12) | Cash runway into 2H22 and minor de...

HEIDELBERG PHARMA (BUY, TP EUR12) | Cash runway into 2H22 and minor delay of phase I study of HDP-101 :

Olga Smolentseva
  • Olga Smolentseva
HPHA Heidelberg Phar... (Health Care)

HEIDELBERG PHARMA (BUY, TP EUR12) | Successful private placement highl...

HEIDELBERG PHARMA (BUY, TP EUR12) | Successful private placement highlights specialists’ interest :

 PRESS RELEASE
HPHA Heidelberg Phar... (Health Care)

DGAP-News: Heidelberg Pharma gibt Update zur klinischen Phase I/IIa-St...

DGAP-News: Heidelberg Pharma AG / Schlagwort(e): Sonstiges Heidelberg Pharma gibt Update zur klinischen Phase I/IIa-Studie mit dem ATAC-Kandidaten HDP-101 in den USA 07.09.2021 / 07:21 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PRESSEMITTEILUNG Heidelberg Pharma gibt Update zur klinischen Phase I/IIa-Studie mit dem ATAC-Kandidaten HDP-101 in den USA - Kompatibilitätstests für geschlossenes Infusionssystem mit HDP-101 erfolgreich abgeschlossen- Versand der Studienmedikation in die USA in Vorbereitung- Vertrag mit erstem Studienzentrum, ...

 PRESS RELEASE
HPHA Heidelberg Phar... (Health Care)

DGAP-News: Heidelberg Pharma Provides Update on Phase I/IIa Clinical T...

DGAP-News: Heidelberg Pharma AG / Key word(s): Miscellaneous Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US 07.09.2021 / 07:21 The issuer is solely responsible for the content of this announcement.   PRESS RELEASE Heidelberg Pharma provides update on Phase I/IIa clinical trial with ATAC candidate HDP-101 in the US - Compatibility tests for closed infusion system with HDP-101 successfully completed- Shipping of study medication to the US in preparation- Contract signed with first study center, MD Anderson Cancer Ce...

Olga Smolentseva
  • Olga Smolentseva
HPHA Heidelberg Phar... (Health Care)

HEIDELBERG PHARMA: H1 2021 brings closer to value inflection point | ...

HEIDELBERG PHARMA - BUY | EUR12 (+60%) H1 2021 brings closer to value inflection point Phase I/II study of HDP-101 is now expected to start recruitment in Q3 Partners are moving along with ATACs development Reiterating BUY rating and TP EUR12

Olga Smolentseva
  • Olga Smolentseva
HPHA Heidelberg Phar... (Health Care)

HEIDELBERG PHARMA (BUY, TP EUR12) | Cash runway into 2H22 and minor de...

HEIDELBERG PHARMA (BUY, TP EUR12) | Cash runway into 2H22 and minor delay of phase I study of HDP-101 :

Olga Smolentseva
  • Olga Smolentseva
HPHA Heidelberg Phar... (Health Care)

HEIDELBERG PHARMA (BUY, TP EUR12) | Successful private placement highl...

HEIDELBERG PHARMA (BUY, TP EUR12) | Successful private placement highlights specialists’ interest :

 PRESS RELEASE
HPHA Heidelberg Phar... (Health Care)

DGAP-News: Heidelberg Pharma gibt Update zur klinischen Phase I/IIa-St...

DGAP-News: Heidelberg Pharma AG / Schlagwort(e): Sonstiges Heidelberg Pharma gibt Update zur klinischen Phase I/IIa-Studie mit dem ATAC-Kandidaten HDP-101 in den USA 07.09.2021 / 07:21 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PRESSEMITTEILUNG Heidelberg Pharma gibt Update zur klinischen Phase I/IIa-Studie mit dem ATAC-Kandidaten HDP-101 in den USA - Kompatibilitätstests für geschlossenes Infusionssystem mit HDP-101 erfolgreich abgeschlossen- Versand der Studienmedikation in die USA in Vorbereitung- Vertrag mit erstem Studienzentrum, ...

 PRESS RELEASE
HPHA Heidelberg Phar... (Health Care)

DGAP-News: Heidelberg Pharma Provides Update on Phase I/IIa Clinical T...

DGAP-News: Heidelberg Pharma AG / Key word(s): Miscellaneous Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US 07.09.2021 / 07:21 The issuer is solely responsible for the content of this announcement.   PRESS RELEASE Heidelberg Pharma provides update on Phase I/IIa clinical trial with ATAC candidate HDP-101 in the US - Compatibility tests for closed infusion system with HDP-101 successfully completed- Shipping of study medication to the US in preparation- Contract signed with first study center, MD Anderson Cancer Ce...

Olga Smolentseva
  • Olga Smolentseva
HPHA Heidelberg Phar... (Health Care)

HEIDELBERG PHARMA: H1 2021 brings closer to value inflection point | ...

HEIDELBERG PHARMA - BUY | EUR12 (+60%) H1 2021 brings closer to value inflection point Phase I/II study of HDP-101 is now expected to start recruitment in Q3 Partners are moving along with ATACs development Reiterating BUY rating and TP EUR12

Olga Smolentseva
  • Olga Smolentseva
HPHA Heidelberg Phar... (Health Care)

HEIDELBERG PHARMA (BUY, TP EUR12) | Cash runway into 2H22 and minor de...

HEIDELBERG PHARMA (BUY, TP EUR12) | Cash runway into 2H22 and minor delay of phase I study of HDP-101 :

Olga Smolentseva
  • Olga Smolentseva
HPHA Heidelberg Phar... (Health Care)

HEIDELBERG PHARMA (BUY, TP EUR12) | Successful private placement highl...

HEIDELBERG PHARMA (BUY, TP EUR12) | Successful private placement highlights specialists’ interest :

 PRESS RELEASE
HPHA Heidelberg Phar... (Health Care)

DGAP-News: Heidelberg Pharma gibt Update zur klinischen Phase I/IIa-St...

DGAP-News: Heidelberg Pharma AG / Schlagwort(e): Sonstiges Heidelberg Pharma gibt Update zur klinischen Phase I/IIa-Studie mit dem ATAC-Kandidaten HDP-101 in den USA 07.09.2021 / 07:21 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PRESSEMITTEILUNG Heidelberg Pharma gibt Update zur klinischen Phase I/IIa-Studie mit dem ATAC-Kandidaten HDP-101 in den USA - Kompatibilitätstests für geschlossenes Infusionssystem mit HDP-101 erfolgreich abgeschlossen- Versand der Studienmedikation in die USA in Vorbereitung- Vertrag mit erstem Studienzentrum, ...

 PRESS RELEASE
HPHA Heidelberg Phar... (Health Care)

DGAP-News: Heidelberg Pharma Provides Update on Phase I/IIa Clinical T...

DGAP-News: Heidelberg Pharma AG / Key word(s): Miscellaneous Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US 07.09.2021 / 07:21 The issuer is solely responsible for the content of this announcement.   PRESS RELEASE Heidelberg Pharma provides update on Phase I/IIa clinical trial with ATAC candidate HDP-101 in the US - Compatibility tests for closed infusion system with HDP-101 successfully completed- Shipping of study medication to the US in preparation- Contract signed with first study center, MD Anderson Cancer Ce...

Olga Smolentseva
  • Olga Smolentseva
HPHA Heidelberg Phar... (Health Care)

HEIDELBERG PHARMA: H1 2021 brings closer to value inflection point | ...

HEIDELBERG PHARMA - BUY | EUR12 (+60%) H1 2021 brings closer to value inflection point Phase I/II study of HDP-101 is now expected to start recruitment in Q3 Partners are moving along with ATACs development Reiterating BUY rating and TP EUR12

Olga Smolentseva
  • Olga Smolentseva
HPHA Heidelberg Phar... (Health Care)

HEIDELBERG PHARMA (BUY, TP EUR12) | Cash runway into 2H22 and minor de...

HEIDELBERG PHARMA (BUY, TP EUR12) | Cash runway into 2H22 and minor delay of phase I study of HDP-101 :

Olga Smolentseva
  • Olga Smolentseva
HPHA Heidelberg Phar... (Health Care)

HEIDELBERG PHARMA (BUY, TP EUR12) | Successful private placement highl...

HEIDELBERG PHARMA (BUY, TP EUR12) | Successful private placement highlights specialists’ interest :

ResearchPool Subscriptions

Get the most out of your insights

Get in touch